Clinical Trials Logo

RAD51B Gene Mutation clinical trials

View clinical trials related to RAD51B Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT06392841 Not yet recruiting - BRCA2 Gene Mutation Clinical Trials

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

HARMONY
Start date: December 2024
Phase: Phase 2
Study type: Interventional

This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.

NCT ID: NCT03377556 Completed - BRCA1 Gene Mutation Clinical Trials

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Start date: March 3, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.